← Back to Search

Topical Gel

LEV102 Topical Gel in Acquired Blepharoptosis

Phase 1 & 2
Waitlist Available
Research Sponsored by Levation Pharma, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2-5

Summary

This trial tests a one-time application of a special medicine on the upper eyelids of adults with drooping eyelids. The goal is to see if the medicine can lift the eyelids. About 30 participants will be involved.

Eligible Conditions
  • Droopy Eyelid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 2-5
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 2-5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability])
Secondary study objectives
Upper Eyelid Height

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LEV102 Topical Gel, 2.0%Experimental Treatment1 Intervention
Group II: LEV102 Topical Gel, 1.0%Experimental Treatment1 Intervention
Group III: VehiclePlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LEV102 1.0%
2023
Completed Phase 2
~40
LEV102 2.0%
2023
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Levation Pharma, Ltd.Lead Sponsor
Houman D Hemmati, MD PhDStudy ChairLevation Pharma, Ltd.

Media Library

LEV102 (Topical Gel) Clinical Trial Eligibility Overview. Trial Name: NCT05715346 — Phase 1 & 2
Droopy Eyelid Research Study Groups: LEV102 Topical Gel, 2.0%, LEV102 Topical Gel, 1.0%, Vehicle
Droopy Eyelid Clinical Trial 2023: LEV102 Highlights & Side Effects. Trial Name: NCT05715346 — Phase 1 & 2
LEV102 (Topical Gel) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05715346 — Phase 1 & 2
~12 spots leftby Dec 2025